Low-risk gestational trophoblastic neoplasia and methotrexate resistance: Predictors of response to treatment with actinomycin D and need for combination chemotherapy

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 55, Issue 7-8, 2010, Pages 279-284

  Growdon, Whitfield B ^a,b   Wolfberg, Adam J ^a,b   Goldstein, Donald P ^c   Feltmate, Colleen M ^a,b   Chinchilla, Manuel E ^a,b   Lieberman, Ellice S ^a,b   Berkowitz, Ross S ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Trophoblastic Tumor Registry   (United States)

Author keywords

Gestational trophoblastic disease; Molar pregnancy

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; DACTINOMYCIN; METHOTREXATE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CYCLOPHOSPHAMIDE; ETOPOSIDE; MAC COMBINATION;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; HUMAN; HYDATIDIFORM MOLE; MEDICAL RECORD REVIEW; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TROPHOBLASTIC TUMOR; BLOOD; DRUG RESISTANCE; MIDDLE AGED; PATHOLOGY; PREGNANCY; REGISTER; REMISSION; UTERUS CANCER;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HUMANS; METHOTREXATE; MIDDLE AGED; PREGNANCY; REGISTRIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; UTERINE NEOPLASMS;

EID: 77957274072     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Wolfberg AJ, Feltmate C, Goldstein DP, et al: Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy. Obstet Gynecol 2004;104: 551-554
2. Berkowitz RS, Goldstein DP: Chorionic tumors. N Engl J Med 1996;335:1740-1748
3. Goto S, Yamada A, Ishizuka T, et al: Development of postmolar trophoblastic disease after partial molar pregnancy. Gynecol Oncol 1993;48:165-170
4. Bagshawe KD, Lawler SD, Paradinas FJ, et al: Gestational trophoblastic tumours following initial diagnosis of partial hydatidiform mole. Lancet 1990;335:1074-1076
5. Kohorn EI: The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: Description and critical assessment. Int J Gynecol Cancer 2001;11:73-77
6. Ngan HY, Bender H, Benedet JL, et al: Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet Suppl 1 2003;83:175-177
7. Osborne R, Gerulath A: What is the best regimen for low-risk gestational trophoblastic neoplasia? A review. J Reprod Med 2004;49:602-616
8. Growdon WB, Wolfberg AJ, Goldstein DP, et al: Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol 2009;112: 353-357
9. El-Helw LM, Hancock BW: Treatment of metastatic gestational trophoblastic neoplasia. Lancet Oncol 2007;8:715-724
10. Lurain JR, Singh DK, Schink JC: Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. J Reprod Med 2006;51:767-772
11. Feltmate CM, Growdon WB, Wolfberg AJ, et al: Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy. J Reprod Med 2006;51:902-906
12. Growdon WB, Wolfberg AJ, Feltmate CM, et al: Postevacuation hCG levels and risk of gestational trophoblastic neoplasia among women with partial molar pregnancies. J Reprod Med 2006;51:871-874
13. Berkowitz RS, Goldstein DP: Current management of gestational trophoblastic diseases. Gynecol Oncol 2009;112:654-662
14. Homesley HD: Single-agent therapy for nonmetastatic and low-risk gestational trophoblastic disease. J Reprod Med 1998;43:69-74
15. Khan F, Everard J, Ahmed S, et al: Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: Efficacy, acute and long-term effects. Br J Cancer 2003; 89:2197-2201
16. Hertz R, Lewis J, Jr., Lipsett MB: Five year's experience with the chemotherapy of metastatic choriocarcinoma and related trophoblastic tumors in women. Am J Obstet Gynecol 1961; 82:631-640
17. Soper JT, Clarke-Pearson DL, Berchuck A, et al: 5-day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol Oncol 1994;54:76-9
18. Kohorn EI: Is lack of response to single-agent chemotherapy in gestational trophoblastic disease associated with dose scheduling or chemotherapy resistance? Gynecol Oncol 2002;85:36-39
19. Hoekstra AV, Lurain JR, Rademaker AW, et al: Gestational trophoblastic neoplasia: Treatment outcomes. Obstet Gynecol 2008;112:251-258
20. Chan KK, Huang Y, Tam KF, et al: Single-dose methotrexate regimen in the treatment of low-risk gestational trophoblastic neoplasia. Am J Obstet Gynecol 2006;195:1282-1286
21. Newlands ES: The management of recurrent and drug-resistant gestational trophoblastic neoplasia (GTN). Best Pract Res Clin Obstet Gynaecol 2003;17:905-923
22. McNeish IA, Strickland S, Holden L, et al: Low-risk persistent gestational trophoblastic disease: Outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 2002;20:1838-1844
23. Osborne R, Filiaci V, Schink J, et al: A randomized phase III trial comparing weekly parenteral methotrexate and "pulsed" dactinomycin as primary management for low-risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecol Oncol 2008;108:S2
24. Alazzam M, Tidy J, Hancock BW, et al: First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev:CD007102, 2009
25. Wolfberg AJ, Berkowitz RS, Goldstein DP, et al: Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy. Obstet Gynecol 2005;106:548-552